Mar 16, 2023

New chair has extensive experience in digital health and data-driven healthcare strategies. Michael Barbella, Managing Editor03.16.23 FEops has appointed Euan S. Thomson, Ph.D., as board chairman, succeeding veteran medical device executive Rob Michiels, who remains an independent board member. “Having extensive experience in digital health and data driven healthcare strategies, Euan Thomson is the ideal person to help FEops expand its unique digital twin technology to other digital health indications.” Michiels said. “I am thrilled to continue to support FEops in this substantial expansion of medical technology reach as an independent board member” FEops has made significant progress with rollout of its HEARTguide structural heart planning software based on digital twin technologies. The PREDICTLAA randomized clinical trial demonstrated the benefits of the digital twin approach when compared to conventional planning techniques. FEops now intends expanding this unique, digital twin approach to other applications. Thomson will work with the management team to support this expanded digital health strategy. “I am grateful for the trust from the entire FEops team and its investors, and I’m looking forward to what we will achieve together. With what I have seen from FEops so far, I genuinely believe in the potential of FEops and truly look forward to expand together in new areas,” Thomson said. The FEops HEARTguide cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy, preoperatively. FEops HEARTguide is available in the United States for use in LAAo with WATCHMAN, WATCHMAN FLX, and Amplatzer Amulet; in the European Union, United Kingdom, Canada, and Australia, FEops HEARTguide is available for use in TAVI and LAAo. FEops HEARTguide has to date been used worldwide in more than 6,500 patients in over 314 hospitals in more than 27 countries. Such insights have the power to improve clinical outcomes in real-world hospital settings, as well as to accelerate research and development of novel device-based solutions. “With Rob Michiels and Euan Thomson as independent board member and non-executive chairman in the FEops board, we combine a wealth of experience in the structural heart and the digital health industry. We feel privileged that both have chosen to support FEops in its plan to alter the course of structural heart and other diseases with our game-changing predictive digital twin technology” FEops Co-Founder/CEO Matthieu De Beule Ph.D., said. Privately held FEops, headquartered in Gent, Belgium, is a digital health scale-up altering the course of heart disease by providing physicians with digital tools to treat the right patients with the right technology at the right time. FEops is supported by Valiance Advisors, Capricorn partners, PMV and the EIC Fund. Trending